Affimed (AFMD) – Trader Talk
-
Affimed (AFMD) Gains Following Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells
-
Affimed (AFMD) Climbs 40% Following Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
-
-
-
-
-
-
-
Back to AFMD Stock Lookup